PepGen Inc. (PEPG)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
PEPG Chart
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls
On Tuesday, PepGen Inc. PEPG announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the company can review results from the 10 mg/kg cohort.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy
PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PepGen Inc. (PEPG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has PepGen Inc. ever had a stock split?
PepGen Inc. Profile
| Biotechnology Industry | Healthcare Sector | James G. McArthur CEO | NASDAQ (NGS) Exchange | 713317105 Cusip |
| US Country | 79 Employees | - Last Dividend | - Last Split | 6 May 2022 IPO Date |
Overview
PepGen Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that was established in 2018. The company's primary focus is on developing oligonucleotide therapeutics aimed at treating severe neuromuscular and neurologic diseases. With a dedicated approach to harnessing the potential of EDO peptides and oligonucleotide therapies, PepGen Inc. strives to bring innovative treatments forward for conditions that currently have limited therapeutic options.
Products and Services
- PGN-EDO51:
- PGN-EDODM1:
- EDO Therapeutic Candidates:
Currently in Phase 2 clinical trial, PGN-EDO51 is PepGen Inc.'s leading product candidate. This EDO peptide is being developed to treat patients with Duchenne muscular dystrophy (DMD), a severe muscle wasting disorder. By advancing this treatment into clinical trials, the company aims to address the tremendous need for effective DMD therapies.
PepGen Inc. is also developing PGN-EDODM1, an EDO peptide-conjugated phosphorodiamidate morpholino oligomer (PMO) that has entered Phase 1 clinical trial for the treatment of myotonic dystrophy type 1. This condition, another serious neuromuscular disease, affects adults and children, leading to life-limiting muscle weakness. PGN-EDODM1 represents a pioneering step towards addressing this unmet medical need.
The company has a pipeline of EDO therapeutic candidates, including PGN-EDO53, PGN-EDO45, and PGN-EDO44, which are also aimed at treating Duchenne muscular dystrophy (DMD). These additional EDO peptides highlight PepGen Inc.'s commitment to developing a range of potential DMD treatments, offering hope for improved outcomes for patients afflicted by this debilitating condition.
Contact Information
